TSTakashi Saika

Takashi Saika

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takashi Saika has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?

    by Kensuke Bekku, Takashi Saika, Yasuyuki Kobayashi, Ryo Kioshimoto, Taiki Kanbara, Yasutomo Nasu, Hiromi Kumon

    The clinical impact of salvage surgery after chemotherapy on cancer survival of patients with metastatic urothelial carcinoma is controversial. We aimed to verify the clinical role of salvage surgery by analyzing the long-term outcome in patients with urothelial carcinoma treated by chemotherapy. Between 2003 and 2010 at a single institution, 31 of 47 patients (66%) with metastatic urothelial carcinoma showed objective responses (CR in 4, PR in 27) after multiple courses of cisplatin/gemcitabine/paclitaxel-based chemotherapy, and a cohort of patients with partial response (PR) were retrospectively enrolled. Twelve (10 male and 2 female, median age 64.0 years) of 27 patients with PR underwent salvage surgeries after the chemotherapy: metastatectomy of residual lesions (10 retroperitoneal lymph nodes, 2 lung), and 6 radical surgeries for primary lesions as well. Progression-free survival and overall patient survival rates were analyzed retrospectively and compared with those of patients without salvage surgery. All 12 patients achieved surgical CR. Pathological findings of metastatic lesions showed viable cancer cells in 3 patients. In univariate analysis, sole salvage surgery affected overall survival in 27 patients with PR to the chemotherapy (P = 0.0037). Progression-free survival and overall survival rates in patients with salvage surgery were better than those in 15 PR patients without the surgery (39.8 vs. 0%, and 71.6 vs. 12.1% at 3 years, P = 0.01032 and 0.01048; log-rank test). Salvage surgery for patients with residual tumor who achieve partial response to chemotherapy could have a possible impact on cancer survival.


  • Prostate specific antigen complexed to α‐1‐antichymotrypsin in patients with intermediate prostate specific antigen levels

    by Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Nobuyuki Kusaka, Yoshiyuki Miyaji, Hitoshi Takamoto, Katsuji Takeda, Satoru Uno, Hiromi Kumon, for the Okayama Urological Cancer Collaborating Group

    BACKGROUND: The authors attempted to evaluate prospectively the usefulness of serum prostate specific antigen (PSA) complexed to α‐1‐antichymotrypsin (PSA‐ACT) in the early detection of prostate carcinoma and its ability to discriminate between prostate carcinoma and benign prostatic hyperplasia (BPH), especially among patients with intermediate PSA levels.METHODS: Between December 1999 and August 2000, systematic sextant biopsies were performed on 281 prospective patients with prostate carcinoma who had serum PSA levels between 4.1 ng/mL and 20.0 ng/mL. The serum samples were assayed by using kits that were designed specifically for measuring serum PSA, PSA‐ACT, and free PSA levels. The clinical values of PSA, PSA‐ACT, the free PSA to total PSA ratio (F/T ratio), the free PSA to PSA‐ACT ratio, PSA density (PSAD), and PSA‐ACT density (ACTD) were compared by using receiver operating characteristic (ROC) curve analysis.RESULTS: Biopsy yielded no evidence of malignancy in 198 patients, and prostate carcinoma was confirmed in 83 patients. ROC analysis demonstrated that the area under the curve (AUC) for PSA‐ACT was greater than that for total PSA and was equivalent to that for the F/T ratio in both groups of patients (PSA ranges of 4.1–20.0 ng/mL and 4.1–10.0 ng/mL, respectively). The AUC for the ACTD was greater than the AUC for the PSAD and had the highest value of all parameters.CONCLUSIONS: The measurement of PSA‐ACT represents an alternative to the use of total and free PSA. The ACTD value is the most useful for discriminating between BPH and prostate carcinoma. Cancer 2002;94:1685–91. © 2002 American Cancer Society.DOI 10.1002/cncr.10377


  • Open Access

    Orthotopic neobladder reconstruction in elderly bladder cancer patients

    by Takashi Saika, Bunzo Suyama, Tadashi Murata, Daisuke Manabe, Takushi Kurashige, Yasutomo Nasu, Tomoyasu Tsushima, Hiromi Kumon

    Background: We compared the clinical results of orthotopic neobladder reconstruction in elderly patients and those in younger patients retrospectively in order to verify whether age is a critical factor in selecting a method of urinary diversion.Methods: Following radical cystectomy for bladder cancer, 12 patients aged 75 or older and 17 patients under 75 who underwent orthotopic neobladder reconstruction between January 1992 and May 1999 were investigated in this study. The authors TS and BS were among the surgeons who performed operations for all cases. Of the 12 elderly patients, orthotopic neobladders were constructed according to Hautmann's method in nine cases, Studer's method in one case and Reddy's method in two cases. Of the 17 younger patients, these methods were employed in 12, one and four cases, respectively. Operative procedure, early and late complications, prognosis, continence and voiding pattern were investigated in these patients.Results: The follow‐up periods for elderly and younger groups ranged from 21.3 to 82.7 months and from 8.8 to 94.2 months, respectively. No difference in operation time, amount of bleeding or postoperative length of hospitalization was observed between elderly and younger patients. The rates of early complications in elderly and younger patients were 41.7% and 35.3%, respectively. Late complication rates were 33.3% and 47.1%, respectively. The difference in these complication rates was not statistically significant. One of the elderly and two of the younger patients had local recurrence and metastasis postoperatively. Those three patients had died of their bladder cancer. No statistically significant difference between groups was recognized in either cause‐specific survival or overall survival, nor was there such a difference in relation to micturition/continence.Conclusion: Based on these results, we believe that because age is not a critical factor in the selection of urinary diversion method, neobladder reconstruction following cystectomy for bladder cancer is indicated in elderly patients. As stoma management is difficult for the patients, we consider orthotopic neobladder reconstruction to be the method of choice if the patients' general physical condition allows.


  • Treatment of androgen‐independent prostate cancer with dexamethasone: A prospective study in stage D2 patients

    by Takashi Saika, Nobuyuki Kusaka, Tomoyasu Tsushima, Toyoko Yamato, Teruhisa Ohashi, Bunzo Suyama, Ryoji Arata, Yasutomo Nasu, Hiromi Kumon, Okayama Urological Cancer Collaborating Group (OUCCG)

    Purpose: In order to evaluate the efficacy of dexamethasone in the treatment of Japanese men with androgen‐independent prostate cancer, a prospective study was conducted using prostate‐specific antigen (PSA) as a primary end‐point.Methods: Nineteen Japanese men with stage D2 androgen‐independent prostate cancer were registered and treatment was started. After ruling out anti‐androgen withdrawal syndrome, they were treated with dexamethasone (1.5 mg daily). Patients were monitored for PSA, symptoms, radiologic response, survival rate, time to disease progression, time to treatment failure and complications.Results: Prostate‐specific antigen levels decreased in nine patients (50.0%); five (27.8%) showed a 50% or greater decrease and two (11.1%) showed an 80% or greater decrease. For the nine patients, the mean duration of PSA response was 7.3 months and the median duration was 2.1 months (range, 1.2–27.5+). Bone pain, which was noted in 13 patients at study entry, improved in seven patients (53.8%). Of nine patients who had serial radiographic examinations with bone scan, three (33%) showed partial response, two (22%) were stable and four (44%) showed disease progression. Treatment was well tolerated, except for one patient who suffered a severe pulmonary infection.Conclusion: Dexamethasone decreased PSA levels and produced subjective symptomatic improvement in the patients with stage D2 androgen‐independent prostate cancer.